Quest Diagnostics backs FY23 adjusted EPS view $8.40-$9.00, consensus $8.72

Backs FY23 revenue view $8.83B-$9.03B, consensus $8.97B. Sees FY23 capital expenditures $400M. At a meeting with analysts and investors at its Investor Day, members of the executive leadership team of Quest Diagnostics will discuss the company’s priorities to grow revenues and create shareholder value. The company is also updating its long-term financial outlook to extend from 2023 through 2026. "We have made refinements to our strategy to accelerate growth from our physician and hospital customers, and are building strong platforms to win in the important areas of molecular genomics and oncology as well as consumer health," said Jim Davis, CEO and oresident. "In addition, we have a range of initiatives underway to continue to drive operational productivity while further improving the customer experience. For the 2023 through 2026 period, we expect to generate revenues at a mid single-digit CAGR and adjusted EPS at a high single-digit CAGR."